Transversus Abdominis Plane Block Versus Ilioinguinal Nerve Block for Pain Management in Inguinal Herniorraphy

Summary

This study compares efficacy of transversus abdominis plane block and ilioinguinal nerve block for postoperative pain in patients undergoing inguinal herniorraphy with spinal anesthesia. One-third of the patients will receive standard postoperative pain regimen(control group), one-third will receive a transversus abdominis plane block (with ultrasound guidance) and the last group will receive an ilioinguinal nerve block(with ultrasound guidance) in addition to standard postoperative pain regimen. This study is a Randomized prospective open-label controlled study.

Conditions

• Pain, Postoperative

Interventions

PROCEDURE

Spinal Anesthesia

All patients will be administered 3ml of %0.5 bupivacaine through L3-L4 interspace to acquire motor and sensory blockade

PROCEDURE

Transversus Abdominis Plane Block

Analgesic intervention which will be performed only to Transversus Abdominis Plane Block arm. It requires 20ml of %0.25 bupivacaine administration through a 22 G. x 4 in. (100 mm) Insulated Echogenic Needle with 30° Bevel from midaxillary line between costal margin and anterior superior iliac spine with ultrasound guidance

PROCEDURE

Ilioinguinal Nerve Block

Analgesic intervention which will be performed only to Ilioinguinal Nerve Block arm. It requires 10ml of %0.25 bupivacaine administration through a 22 G. x 3-1/8 in. (80 mm) Insulated Echogenic Needle with 30° Bevel between umbilicus and iliac crest where the nerve is detected with ultrasound guidance

DRUG

Bupivacaine %0.5 (hyperbaric)

DRUG

Bupivacaine %0.25 (isobaric)

DEVICE

25G Quincke needle

DEVICE

Echogenic Needle with 30° bevel

DRUG

Acetaminophen

Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely

DRUG

Tramadol

Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)

Sponsors & Collaborators

• Bozyaka Training and Research Hospital

  lead OTHER

Principal Investigators

• Onur Okur, MD,Resident · Izmir Bozyaka Training and Research Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-02-28

Primary Completion

2015-10-31

Completion

2015-10-31

Countries

• Turkey (Türkiye)

Study Locations